Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

SELL
$43.78 - $63.86 $744,260 - $1.09 Million
-17,000 Reduced 62.5%
10,200 $512,000
Q4 2023

Feb 14, 2024

BUY
$36.35 - $63.02 $988,720 - $1.71 Million
27,200 New
27,200 $1.64 Million

Others Institutions Holding MLTX

About MoonLake Immunotherapeutics


  • Ticker MLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,925,600
  • Market Cap $1.93B
  • Description
  • MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...
More about MLTX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.